Quito, Ecuador, November 10, 2020 — Recently, Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) has received marketing approval from the Regulatory, Control and Surveillance National Agency of Ecuador (La Agencia Nacional de Regulación, Controly Vigilancia Sanitaria — ARCSA) for its proprietary products Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Firebird2® Coronary Rapamycin-Eluting CoCr Stent System (Firebird2®), Firefighter™ PTCA Balloon Catheter (Firefighter™) and FOXTROT™ NC PTCA Balloon Catheter (FOXTROT™ NC).
Firehawk® is a drug-eluting stent (DES) featuring strut in-groove coating and precision target drug-releasing patent technology. It is globally recognized by clinical experts for its innovation. Almost 600 grooves are evenly cut in the strut of Firehawk®, which is made of the hair-thin and extremely hard CoCr alloy. The drug is precisely loaded into the micro grooves by applying fully automatic 3D printing to achieve micro groove-filling. Firehawk® combines the merits of bare metal stent and drug-eluting stent, which allows it to achieve the same clinical efficacy with significantly lower drug loading.
Made of cobalt-chrome tubing using laser cut technology, Firebird2® offers enhanced radial support, improved stent flexibility, and excellent MRI compatibility. The Firefighter™ PTCA Balloon Catheter is designed for coronary dilatation during percutaneous transluminal coronary angioplasty (PTCA) and can be used in conjunction with a coronary stent system to pre-expand the lesion prior to stent implantation. Firefighter™ has relatively lower profile than that of its competitors of the same size, and is made of flexible materials, enabling it to cross stenosis and tortuous lesions multiple times. Being able to accommodate two balloon catheters in a 5F introducer catheter despite its extremely small size, the Firefighter™ PTCA Balloon Catheter allows surgeons to perform complex procedures such as balloon-stent kissing. Featuring excellent cross-ability, traceability and push-ability, FOXTROT™ NC can be used either for pre-expansion of intravascular lesions prior to stent implantation or for precise post-expansion after stent implantation.
The approval of the four MicroPort® products in Ecuador, particularly the Firehawk® stent, not only shows industry recognition of MicroPort® for its outstanding product portfolio in the field of coronary intervention, but also further expands the company’s global presence. Now, the company's coronary interventional products have been introduced to more than 4,000 hospitals in more than 50 countries around the world, covering major markets in Asia Pacific, Europe and South America, and have won the trust and recognition of doctors and patients in clinical applications.
In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with higher-quality, innovative high-end medical devices and integrated solutions.